Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing.

PURPOSE Tumor testing for microsatellite instability and/or mismatch repair-deficiency (MSI/IHC) and clinical prediction models effectively screen for Lynch syndrome (LS)-associated colorectal cancer (CRC) and endometrial cancer (EC), but they have not been assessed for their ability to identify non-LS forms of inherited risk. The aim of this study was to compare MSI/IHC and the PREMM5 prediction model to identify carriers of LS and non-LS pathogenic variants (PVs) among patients with CRC and EC. PATIENTS AND METHODS Data were retrospectively analyzed from two single-institution cohorts: 706 patients with CRC and/or EC referred for genetic evaluation/testing (high-risk cohort) and 1,058 consecutively ascertained patients with CRC (oncology clinic cohort), unselected for familial risk. All participants underwent germline multigene panel testing. PREMM5 scores were calculated from personal/family cancer history. The primary outcome was the proportion of individuals with germline PVs (LS PVs, high-penetrance PVs, and any PVs) who had abnormal MSI/IHC testing and/or PREMM5 score ≥ 2.5%. RESULTS MSI/IHC and PREMM5 had comparable sensitivity for identifying LS carriers in high-risk (89.3% v 85.7%; P = .712) and oncology clinic patients (96.6% v 96.6%; P = 1.000), although MSI/IHC had significantly superior specificity for LS (81.3% v 20.1%; P < .001; 92.3% v 24.3%; P < .001). In both cohorts, PREMM5 had superior sensitivity to MSI/IHC at identifying patients with any high-penetrance PVs and any low-, moderate-, and high-penetrance PVs. Among patients with normal MSI/IHC, PREMM5 identified 84.2% and 83.3% of high-risk patients with CRC/EC and oncology clinic CRC patients with high-penetrance PVs, respectively. CONCLUSION MSI/IHC and PREMM5 effectively identify patients with CRC and/or EC with LS, although MSI/IHC has better specificity for LS. Because PREMM5 identifies non-LS, high-penetrance germline PVs, patients with CRC and/or EC with PREMM5 score ≥ 2.5%, including those with normal MSI/IHC, should be offered multigene panel testing.

[1]  J. Church,et al.  Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis , 2020, Familial Cancer.

[2]  M. Ladanyi,et al.  Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings , 2020, Cancer.

[3]  E. V. Van Allen,et al.  Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma , 2019, Genetics in Medicine.

[4]  Kenneth Offit,et al.  Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Martinelli,et al.  Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Judy C. Boughey,et al.  Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons , 2019, Annals of Surgical Oncology.

[7]  K. Stefánsson,et al.  Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome , 2019, Journal of Medical Genetics.

[8]  M. Goggins,et al.  Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Pérez-Segura,et al.  Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition , 2018, PloS one.

[10]  W. Hahn,et al.  Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer , 2018, Genetics in Medicine.

[11]  Raymond M. Moore,et al.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer , 2018, JAMA.

[12]  S. Gruber,et al.  Germline Genetic Features of Young Individuals With Colorectal Cancer. , 2017, Gastroenterology.

[13]  Masaya Suenaga,et al.  Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Ewout W Steyerberg,et al.  Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Goodfellow,et al.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer , 2017, JAMA oncology.

[16]  Hajime Uno,et al.  Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  John Kidd,et al.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Broaddus,et al.  Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort , 2016, Modern Pathology.

[19]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[20]  H. Correa.  Li–Fraumeni Syndrome , 2016, Journal of Pediatric Genetics.

[21]  Tom Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[22]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[23]  S. Syngal,et al.  Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. , 2015, Gastroenterology.

[24]  Ingrid Marino,et al.  Patients Tested at a Laboratory for Hereditary Cancer Syndromes Show an Overlap for Multiple Syndromes in Their Personal and Familial Cancer Histories , 2015, Oncology.

[25]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[26]  S. Gruber,et al.  Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Randall W Burt,et al.  Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. , 2014, Gastroenterology.

[28]  Randall W Burt,et al.  Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. , 2014, Diseases of the colon and rectum.

[29]  Aung Ko Win,et al.  Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. , 2014, Gastroenterology.

[30]  N. Arber,et al.  The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews. , 2013, European journal of cancer.

[31]  J. Church,et al.  Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Rochelle L. Garcia,et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[33]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  W. Frankel,et al.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. , 2006, Cancer research.

[35]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[36]  Florence Demenais,et al.  Geographical variation in the penetrance of CDKN2A mutations for melanoma. , 2002, Journal of the National Cancer Institute.

[37]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[38]  Ewout W Steyerberg,et al.  The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. , 2011, Gastroenterology.

[39]  Randall W Burt,et al.  ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes , 2015, The American Journal of Gastroenterology.